KN-93 (2-[N-(2-Hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor, Is a Direct Extracellular Blocker of Voltage-Gated Potassium Channels

  1. Saman Rezazadeh,
  2. Thomas W. Claydon and
  3. David Fedida
  1. Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, British Columbia, Canada
  1. Address correspondence to:
    Dr. David Fedida, Department of Cellular and Physiological Sciences, 2350 Health Sciences Mall, Vancouver BC V6T 1Z3, Canada. E-mail: fedida{at}interchange.ubc.ca

Abstract

The effect of Ca2+/calmodulin-dependent protein kinase II (CaMK II) on voltage-gated ion channels is widely studied through the use of specific CaMK II blockers such as 2-[N-(2-hydroxyethyl)]-N-(4methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine (KN-93). The present study demonstrates that KN-93 is a direct extracellular blocker of a wide range of cloned Kv channels from a number of different subfamilies. In all channels tested, the effect of 1 μM KN-93 was independent of CaMK II because 1 μM2-[N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine, phosphate (KN-92), an inactive analog of KN-93, caused similar inhibition of currents. In addition, dialysis of cells with 10 μM CaMK II inhibitory peptide fragment 281-301 (CIP) had no effect on current kinetics and did not prevent the inhibitory effect of KN-93. The IC50 for block of the Kv1.5 channel (used as an example to determine the nature of KN-93 block) was 307 ± 12 nM. KN-93 blocked open channels with little voltage dependence that did not alter the V1/2 of channel activation. Removal of P/C-type inactivation by mutation of arginine 487 to valine in the outer pore region of Kv1.5 (R487V) greatly reduced KN-93 block, whereas enhancement of inactivation induced by mutation of threonine 462 to cysteine (T462C) increased the potency of KN-93 by 4-fold. This suggested that KN-93 acted through promotion and stabilization of C-type inactivation. Importantly, KN-93 was ineffective as a blocker when applied intracellularly, suggesting that CaMK II-independent effects of KN-93 on Kv channels can be circumvented by intracellular application of KN-93.

Footnotes

  • This work was supported by grants from the Heart and Stroke Foundations of British Columbia and Yukon and the Canadian Institutes of Health Research (CIHR) to D.F. S.R. was supported by University of British Columbia Graduate Fellowship. T.W.C. was supported by postdoctoral research fellowship funded by a Focus on Stroke strategic initiative from The Canadian Stroke Network, the Heart and Stroke Foundation, the CIHR Institute of Circulatory and Respiratory Health, and the CIHR/Rx&D Program along with AstraZeneca Canada.

  • S.R. and T.W.C. contributed equally to this work.

  • doi:10.1124/jpet.105.097618.

  • ABBREVIATIONS: Kv, voltage-gated potassium channels; hERG, human ether a-go-go related gene; eag, ether a go-go; KN-93, 2-[N(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine; KN-92, 2-[N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine, phosphate; CaMK II, Ca2+/calmodulin-dependent protein kinase II; CIP, CaMK II inhibitory peptide fragment; HEK, human embryonic kidney; MEM, minimal essential medium.

    • Received October 24, 2005.
    • Accepted December 15, 2005.
« Previous | Next Article »Table of Contents